Skip to main content

Table 6 Factors associated with esophagitis on EGD (multivariable linear mixed effects models, GLMM)

From: Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis

Multivariable GLMM
Parameters Models* OR 95% CI p AUC (95%CI)
Age Model 1 0.98 0.96–1.01 0.289 0.69 (0.60–0.79)
Sex   0.89 0.34–2.31 0.803  
Disease duration   1.00 0.96–1.03 0.925  
PPI   0.50 0.21–1.23 0.133  
mRSS Model 2 1.11 1.04–1.18 0.003 0.76 (0.67–0.84)
Hb Model 3 1.33 1.00–1.77 0.051 0.89 (0.83–0.95
Heartburn Model 4 1.71 0.76–3.83 0.193 0.64 (0.55–0.73)
Regurgitation   1.43 0.59–3.46 0.433  
Dysphagia   1.01 0.46–2.18 0.987  
Esophageal symptoms Model 5 3.25 1.00–10.54 0.049 0.61 (0.52–0.71)
Stomach symptoms   1.43 0.57–3.60 0.443  
Reflux subscale Model 6 1.17 0.60–2.26 0.644 0.60 (0.51–0.69)
Distention/bloating subscale Model 7 0.69 0.43–1.12 0.135 0.66 (0.58–0.75)
Social functioning Model 8 0.70 0.33–1.50 0.362 0.59 (0.50–0.68)
Emotional wellbeing Model 9 0.91 0.43–1.95 0.810 0.64 (0.55–0.73)
Total UCLA GIT 2.0 score Model 10 0.82 0.33–2.02 0.659 0.68 (0.59–0.77)
  1. General linear mixed models. Statistically significant results are highlighted in bold font
  2. *Model 1 contains the covariates age, sex, disease duration and PPI therapy. All other models contain, in addition to the covariates of model 1, the following covariates: model 2: mRSS; model 3: hemoglobin; model 4: the symptoms heartburn, regurgitation, dysphagia, and vomiting; model 5: the symptom clusters “esophageal symptoms” and “stomach symptoms” as per expert opinion; models 6–10: one of the mentioned subscales of UCLA GIT 2.0, respectively the total UCLA GIT 2.0 score
  3. PPI proton pump inhibitors, Hb hemoglobin, mRSS modified Rodnan skin score